Introduction
immediately after operation, needing the institution of more intensive antihypertensive therapy (Figure 1 ) . The mechanism by which recombinant human erythro-
The patient was discharged 12 days later, with her poietin (Epo) increases blood pressure in a substantial blood pressure controlled with captopril 100 mg/day. proportion of uraemic patients is still unclear. In vitro Five days later, she was readmitted for peritoneal studies support changes in endothelial function [1, 2] . dialysis treatment. Her blood pressure was Increased vascular responsiveness to endogenous vaso-140/80 mmHg. Because of peritoneal outflow obstrucconstrictors has also been shown in uraemic patients tion, omental wrapping of the catheter was suspected receiving Epo [3, 4] . and a laparatomy was performed. One hour prior to We previously observed that antiplatelet therapy laparatomy six platelet packs were transfused, the may protect these patients from the development of patient again developing severe hypertension, which hypertension induced by Epo [5, 6 ] . One hypothesis to did not respond to analgesic or anxiolytic drugs explain this finding may be the influence of hyperactive (Figure 1 ). platelets on the function of an abnormal endothelium.
In order to rule out the influence of volume expanWe study the effect of Epo in an end-stage renal sion on the hypertensive crises following platelet transfailure patient with severe thrombocytopenia and fusions, 350 ml of saline 0.9% (the estimated plasma the changes in her blood pressure after platelet transfusions.
Case report
A 15-year-old female patient with Flechner's syndrome (macrothrombocytopenia, deafness and Alport-like nephropathy) was referred to our service for end-stage renal failure. She underwent splenectomy at the age of 10. Renal failure was detected at the age of 13, with progressive deterioration in the last few months. Epo therapy (25 U/kg/b.i.w) was begun 3 months earlier due to severe anaemia. Blood pressure was normal prior to Epo therapy and a slight increase was observed in the last few weeks for which 20 mg/day nitrendipine was administered. The patient had uneventfully received several platelet transfusions in the previous years.
She was admitted to the hospital for peritoneal catheter placement. At admission, her blood pressure was 140/90 mmHg and laboratory studies showed: haematocrit 26%, haemoglobin 88 g/l, platelet count 3×103/mm3, and creatinine clearance 8.5 ml/min. Six platelet packs were transfused before a peritoneal Fig. 1 . Haematocrit, platelet count and mean arterial pressure (MAP) during the first two hypertensive crises following platelet catheter was surgically placed, using local anaesthetic. volume of six packed platelet units) were infused over sions without Epo no longer triggered arterial hypertension. This observation raises two major questions: 2 h, 15 days after the last hypertensive crisis. A peak blood pressure of 150/100 was recorded 2 h after the (1 ) what is the mechanism by which platelet transfusions increased blood pressure in this thromboinfusion, with the patient remaining normotensive ( BP<130/80 mmHg) for the following 2 days. cytopenic end-stage renal failure patient? and, (2 ) why did the blood pressure increase only in conjunction Despite the continued Epo therapy, there was no need for antihypertensive drugs during the following with Epo therapy?
Hypertensive crises following blood transfusions are months.
Seven months later, the patient received six platelet very uncommon. Increases in blood pressure along with encephalopathy or cerebral haemorrhage followpacks before the extraction of a tooth. She had normal blood pressure ( 120/70 mmHg) prior to platelet trans-ing blood transfusions have been described only in patients with several types of haemolytic anaemia and fusion and her haematocrit was 28%. Two hours after platelet transfusion, the blood pressure was normal renal function (prototype of chronic endogenous overproduction of erythropoietin) [7] [8] [9] [10] . The 180/110 mmHg. She was discharged the next day on propanolol 120 mg plus nifedipine 60 mg/day. During infusion of vasoactive substances from platelets has been mentioned for explain these clinical events [7 ] . the following 24 h, the patient remained severely hypertensive at home despite treatment, complaining of Platelet packs are very rich in substances which potentially have vasopressor effects (serotonin, thromboxepigastric pain, vomiting and 36 h later was readmitted with tonic-clonic convulsions and a blood pressure of ane). In addition, intracellular concentrations of these substances are high in normal platelets, and through 250/150 mmHg. Although she was treated with intensive antihypertensive therapy (sodium nitroprussiate the mechanism of aggregation, they can be locally released in peripheral circulation. Therefore the infuand labetalol ), the control of blood pressure was very difficult. Epo therapy was withdrawn. Fifteen days sion or release of these substances from aggregated platelets may explain the increase in blood pressure later, blood pressure was normal (120/80 mmHg) without medication.
only if the recipient of the transfusion was especially susceptible to their vasoactive effects. According to the One month later, it was necessary to remove the peritoneal catheter due to complicated peritonitis with events observed in this case, it seemed that Epo made the patient susceptible to the potential vasopressor catheter malfunction and Candida overgrowth. The patient received six platelet packs before the removal effect of platelet transfusion.
A shift in prostanoid balance and increased synthesis of the peritoneal catheter. No modifications in the blood pressure were observed after transfusion, and release of endothelin-1 (ET-1) are thought to be primary effects of Epo in endothelium [1,2]. However, remaining normotensive without antihypertensive drugs. Her haematocrit was maintained above 25% by these changes in endothelial function do not seem to be important enough by themselves to cause significant red blood cell transfusions. Forty-five days later, a new peritoneal catheter was placed with the same protocol clinical events in most patients treated with Epo. It is likely, however, that these changes, may impair of platelet transfusion and without Epo therapy. No modification in the blood pressure was observed. vascular responsiveness to endogenous vasoconstrictors, such as noradrenaline or angiotensin II [3, 4] . In order to confirm the association between hypertensive crises and platelet transfusions only when she Furthermore, increase in local synthesis and secretion of ET-1 may amplify the effects of other potential was on Epo therapy, we asked parents for permission to re-institute Epo therapy for 1 month (25 U/Kg/b.iw) vasoconstrictors, such as serotonin [11] . At the same time, the interaction of more active platelets with and then closely check blood pressure changes following the transfusion of three platelet packs. Before endothelium could lead to the release of other substances from aggregated platelets such as TGFb, platelet transfusion, the patient's blood pressure was 120/70 mmHg without medication. Immediately after PDGF, FGF, etc., which are known to potentiate ET-1 synthesis and promote the proliferation of endothe transfusion, blood pressure rose to 180/120 mmHg and remained so for 4 h, until nifedipine, propanolol, thelial cells [12, 13] . In addition, thrombin, which is formed after activation of the coagulation cascade can and hydralazine were instituted. During the following 5 days these drugs were required for blood pressure also stimulate the formation of ET-1, even potentiating the in vitro effects of Epo on ET-1 synthesis and control and were tapered thereafter. Ten days later, the patient's blood pressure was normal with no need secretion [2] .
The results from the studies quoted above, may help of antihypertensive medication, despite the continued Epo therapy.
to explain hypothetically the co-stimulatory effect of more active platelets in Epo-induced hypertension. On a theoretical and speculative basis, they may also Discussion explain why this patient showed hypertensive crises after platelet transfusions. However, further studies will be necessary to unveil the role of platelets in the This end-stage renal failure patient with macrothrombocytopenia developed severe auto-limited crises of physiopathology of arterial hypertension and the link between platelets and Epo-induced hypertension in arterial hypertension after platelet transfusions only when she was receiving Epo therapy. Platelet transfu-end-stage renal failure patients.
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